Elsevier regrets faux journals

Share this article:
Elsevier came under fire for a series of deceptive publications published in Australia between 2000 and 2005. The six journals in question, published by Elsevier's Excerpta Medica, resembled legitimate journals, but were in fact sponsored compilations created “on behalf of pharmaceutical clients…and lack[ing] the proper disclosures,” said Michael Hanson, CEO of Elsevier's health sciences division, in a statement. “This was an unacceptable practice, and we regret that it took place.”

One of the journals, Australasian Journal of Bone and Joint Medicine, was allegedly produced entirely by Merck to promote Vioxx, according to a report in The Australian.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.